Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Public ClinicalTrials.gov record NCT02673333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Study identification
- NCT ID
- NCT02673333
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2016
- Primary completion
- Jan 10, 2019
- Completion
- Jan 31, 2027
- Last update posted
- Apr 5, 2026
2016 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Michigan (Data or Specimen Analysis Only) | Ann Arbor | Michigan | 48109 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Adrenocortical Carcinoma trials
Other public records listing Adrenocortical Carcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07715903: Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Not yet recruiting
- NCT03127774: Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Active, not recruiting
- NCT03050268: Familial Investigations of Childhood Cancer Predisposition Recruiting
- NCT06066333: Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Recruiting
- NCT04119024: Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Recruiting
- NCT04358107: Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02673333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2026 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02673333 live on ClinicalTrials.gov.